OncoMatch/Clinical Trials/NCT04742634
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Is NCT04742634 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including DEC-C and MyeloSeq-HD for myelodysplastic syndromes.
Treatment: DEC-C · MyeloSeq-HD — The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will perform ultra-deep, error-corrected panel-based sequencing (MyeloSeq-HD) at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable molecular MRD with DEC-C to determine if pre-emptive, MRD-guided therapy with DEC-C decreases relapse rates and improves progression-free survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Myelodysplastic Syndrome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: allogeneic hematopoietic cell transplant
who have received an allogeneic hematopoietic cell transplant
Cannot have received: investigational agent
Not currently receiving any investigational agents
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.0 X 10^9/L and platelets ≥ 50 X 10^9/L
Kidney function
Creatinine clearance ≥ 30 mL/min using Cockcroft-Gault Formula
Liver function
Total bilirubin ≤ 1.5 x IULN (unless due to hemolysis or Gilbert's disease, per PI discretion); AST(SGOT)/ALT(SGPT) ≤ 3.0 IULN
Absolute neutrophil count (ANC) ≥ 1.0 X 10^9/L and platelets ≥ 50 X 10^9/L. Total bilirubin ≤ 1.5 x IULN. AST(SGOT)/ALT(SGPT) ≤ 3.0 IULN. Creatinine clearance ≥ 30 mL/min using Cockcroft-Gault Formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04742634 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages